- The Nation of Georgia's Prime Minister and Minister of Health have issued an Emergency Use Authorization for NRx Pharmaceuticals Inc's NRXP intravenous Zyesami (aviptadil) to treat critical COVID-19 patients.
- The company says that the first doses will arrive in the Nation of Georgia within 24 hours.
- Last week, NRx validated the first commercial formulation, with one year or greater stability, of its Zyesami COVID-19 treatment.
- Zyesami also prevented the sharp rise in cytokines and was associated with a significant decrease in 60-day mortality.
- Zyesami (aviptadil) is a synthetic form of Vasoactive Intestinal Polypeptide.
- Price Action: NRXP shares are up 14% at $21.31 during the market session on the last check Tuesday.
- Related content: Benzinga's Full FDA Calendar.
© 2025 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in
